- Home
- MBRX vs APVO Comparison
MBRX vs APVO Comparison
Compare MBRX & APVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MBRX
- APVO
- Stock Information
- Founded
- MBRX 2015
- APVO 2016
- Country
- MBRX United States
- APVO United States
- Employees
- MBRX N/A
- APVO N/A
- Industry
- MBRX Biotechnology: Pharmaceutical Preparations
- APVO Biotechnology: Pharmaceutical Preparations
- Sector
- MBRX Health Care
- APVO Health Care
- Exchange
- MBRX Nasdaq
- APVO Nasdaq
- Market Cap
- MBRX 23.5M
- APVO 21.7M
- IPO Year
- MBRX 2016
- APVO N/A
- Fundamental
- Price
- MBRX $0.48
- APVO $1.52
- Analyst Decision
- MBRX Strong Buy
- APVO
- Analyst Count
- MBRX 4
- APVO 0
- Target Price
- MBRX $5.00
- APVO N/A
- AVG Volume (30 Days)
- MBRX 2.4M
- APVO 4.6M
- Earning Date
- MBRX 11-12-2025
- APVO 11-10-2025
- Dividend Yield
- MBRX N/A
- APVO N/A
- EPS Growth
- MBRX N/A
- APVO N/A
- EPS
- MBRX N/A
- APVO N/A
- Revenue
- MBRX N/A
- APVO N/A
- Revenue This Year
- MBRX N/A
- APVO N/A
- Revenue Next Year
- MBRX N/A
- APVO N/A
- P/E Ratio
- MBRX N/A
- APVO N/A
- Revenue Growth
- MBRX N/A
- APVO N/A
- 52 Week Low
- MBRX $0.25
- APVO $1.32
- 52 Week High
- MBRX $3.65
- APVO $298.00
- Technical
- Relative Strength Index (RSI)
- MBRX 51.87
- APVO 44.41
- Support Level
- MBRX $0.44
- APVO $1.48
- Resistance Level
- MBRX $0.52
- APVO $1.65
- Average True Range (ATR)
- MBRX 0.04
- APVO 0.13
- MACD
- MBRX -0.00
- APVO 0.01
- Stochastic Oscillator
- MBRX 57.48
- APVO 6.10
About MBRX Moleculin Biotech Inc.
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.
About APVO Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.